Clinical Trial Update: VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating VNP40101M for relapsed or refractory locally advanced or metastatic small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• VNP40101M

Snippet

Sponsor: Vion Pharmaceuticals | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED